10/07/2026 | Press release | Distributed by Public on 10/07/2026 08:24
COMPANY ANNOUNCEMENT
When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company.
Read Announcement View Product PhotosLeader Formulas, LLC. of Tomball, TX, is voluntarily recalling one (1) lot of RAPTURE Pre workout, a dietary supplement powder because it was found to contain 1,3-Dimethylamylamine (DMAA) and sold at the consumer level. Using DMAA can result in elevated blood pressure and could lead to cardiovascular problems, including heart attack, shortness of breath and tightening of the chest.
The product is used as a dietary supplement and is packaged in 450g round plastic containers with red and black lettering and a rhinoceros print seal on top of the container. The affected RAPTURE Preworkout lots include the following lot number (260327-4). The product can be identified by the following:
|
PRODUCT |
UPC |
|
Rainbow Twist |
710154236506 |
|
Electric Lemonade |
710143 236513 |
|
Berry Mojito |
710154236544 |
RAPTURE Preworkout was distributed between 1/29/25 to 5/25/26 Nationwide to retail and via internet through the company website (www.leaderformulas.com).
The issue was discovered in the product during testing by the FDA. Leader Formulas, LLC. is notifying its distributors and customers by mail and is arranging for return of all recalled products. Consumers who have purchased the RAPTURE Preworkout products which are being recalled should stop using the products and return to the place of purchase for a full refund.
Leader Formulas, LLC. has not received any reports of adverse events related to this recall.
Consumers with questions regarding this recall may contact Leader Formulas, LLC. by email at [email protected] or by phone at 832-855-7562 Monday through Friday 9 AM to 5 PM CT.
Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
10/07/2026